- Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Conferences
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
More ▼
Key statistics
On Friday, Pliant Therapeutics Inc (9PT:STU) closed at 11.30, 6.60% above its 52-week low of 10.60, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.00 |
---|---|
High | 11.30 |
Low | 11.00 |
Bid | 11.00 |
Offer | 11.40 |
Previous close | 11.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 60.33m |
Free float | 56.46m |
P/E (TTM) | -- |
Market cap | 731.75m USD |
EPS (TTM) | -2.86 USD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼